4D Molecular Therapeutics, Inc. (FDMT) News
Track canonical SquawkNews coverage tagged to FDMT, 4D Molecular Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 17 indexed stories across 10 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
4D Molecular Therapeutics Price Target Raised to $33.00/Share From $29.00 by B of A Securities
Ratings actions from Benzinga
NEWS | Sep 29, 2026, 12:33 PM UTC
L
OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
Shares of Ocular Therapeutix (OCUL) dropped more than 22% on Monday as investors reacted to upbeat late-stage results from two competitors targeting the same crowded market for longer-lasting wet age-related macular dege
EQUITY | Sep 28, 2026, 05:16 PM UTC
L
4D Molecular Therapeutics enrolls first patients in Phase 3 4SIGHT; SPECTRA shows +10.8 BCVA gain, 61% treatment-burden reduction
4D Molecular Therapeutics announced first patient enrollments in the global Phase 3 4SIGHT trial of 4D-150 for DME and reported 2-year SPECTRA data showing clinical activity and reduced treatment burden.Key Highlights:Or
REGULATION | Sep 28, 2026, 12:16 PM UTC
L
4D Molecular Therapeutics (FDMT) Starts Phase 3 4SIGHT Trial in DME
4D Molecular Therapeutics initiated 4SIGHT, a Phase 3 trial of 4D-150 in diabetic macular edema, with first patients enrolled and FDA RMAT designation noted.Material DetailsContext by AI AnalystThis is a late-stage devel
REGULATION | Sep 28, 2026, 12:01 PM UTC
L
4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
EMERYVILLE, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT; 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with po
NEWS | Sep 28, 2026, 12:01 PM UTC
L
FDMT: 4D-150 gene therapy shows strong safety, efficacy, and commercial momentum in retinal diseases
The session highlighted the progress of a next-gen gene therapy platform, with 4D-150 advancing in wet AMD and DME. Strong clinical data, rapid trial enrollment, and a robust commercial partnership with Otsuka support gl
NEWS | Sep 14, 2026, 11:02 PM UTC
L
FDMT: Gene therapy platform advances with strong phase III momentum, robust safety, and commercial readiness
Revised summary: The session highlighted advances in next-gen gene therapy, with 4D-150 showing strong safety and efficacy in wet AMD and DME. Rapid enrollment and positive feedback support robust phase III trials. Comme
NEWS | Sep 14, 2026, 10:38 PM UTC
L
4DMT Announces New Employment Inducement Grants
EMERYVILLE, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with po
NEWS | Sep 11, 2026, 08:11 PM UTC
L
FDMT - 4DMT Announces New Employment Inducement Grants
FDMT - 4DMT Announces New Employment Inducement Grants
NEWS | Sep 11, 2026, 08:05 PM UTC
L
4D-150 Phase III wet AMD trials fully enrolled; data due next year
4D-150 Phase III trials in wet AMD are fully enrolled. Major data readouts are expected next year for the therapy aimed at reducing treatment burden and preserving vision.
EQUITY | Sep 10, 2026, 03:33 PM UTC
L
FDMT - 4DMT to Participate in Upcoming Investor Conferences
FDMT - 4DMT to Participate in Upcoming Investor Conferences
EQUITY | Aug 25, 2026, 12:01 PM UTC
L
FDMT/4DMT announces new employment inducement grants
FDMT, also known as 4DMT, announces new employment inducement grants, with no further details provided in the feed.
EQUITY | Aug 14, 2026, 08:05 PM UTC
L
4DMT (FDMT) reports Q2 2026 financial results and operational highlights
FDMT—4DMT reports its second quarter 2026 financial results along with operational highlights and expected upcoming milestones.
EARNINGS | Aug 13, 2026, 08:05 PM UTC
H
FDMT Initiated Buy at B.Riley
B.Riley initiates FDMT buy
EQUITY | Jul 31, 2026, 11:55 AM UTC
H
Cantor Initiates DUOT Overweight
Banks initiate coverage on several stocks
EQUITY | Jul 31, 2026, 11:38 AM UTC
H
FDMT Rated Buy
FDMT rated new buy
EQUITY | Jul 31, 2026, 11:23 AM UTC
L
FDMT - per Saturday PR: 4D Molecular Therapeutics' 4D-150 Achieves 78% Overall Treatment Burden Reduction At 2 Years, With 87% Reduction In
FDMT - per Saturday PR: 4D Molecular Therapeutics' 4D-150 Achieves 78% Overall Treatment Burden Reduction At 2 Years, With 87% Reduction In Recently Diagnosed Wet Age-Related Macular Degeneration Subgroup
EQUITY | Jul 20, 2026, 01:15 PM UTC